Oral Oncology
Volume 46, Issue 5 , Pages e29-e33 , May 2010

Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer

  • Jen-Tsun Lin

      Affiliations

    • Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan
    • Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taiwan
    • ,
  • Tung-Hao Chang

      Affiliations

    • Department of Radiation Oncology, ChangHua Christian Medical Center, ChangHua, Taiwan
    • Department of Biomedical Engineering and Environmental Sciences, National Tsing-Hua University, Hsinchu, Taiwan
    • Department of Radiological Technology, Yuanpei University, Hsinchu, Taiwan
    • ,
  • Cheng-Shong Chang

      Affiliations

    • Division of Hematology and Oncology, Department of Medicine, ChangHua Christian Medical Center, ChangHua, Taiwan
    • ,
  • Wen-Hong Wang

      Affiliations

    • Department of Otorhinology, Chang Gung Memorial Hospital, Chia-Yi, Taiwan
    • ,
  • Bi-Wen Su

      Affiliations

    • Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan
    • ,
  • Kuan-Der Lee

      Affiliations

    • Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan
    • ,
  • Pey-Jium Chang

      Affiliations

    • Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taiwan
    • Corresponding Author InformationCorresponding author. Address: Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, No. 3, Po-Zih West Section, Po-Zih, Chiayi 612, Taiwan. Tel./fax: +886 05 3621000.

Received 7 January 2010 ,Revised 16 February 2010 ,Accepted 16 February 2010.

References 

  1. Gunthert U, Stauder R, Mayer B, Terpe H, Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumor progression?. Cancer Surv. 1995;24(1):19–42
  2. Iida N, Bourguignon LYW. New CD44 splice variants associated with human breast cancers. J Cell Physiol. 1995;162(2):127–133
  3. Bourguignon LY, Lokeshwar VA, He H. A CD44-like endothelial cell transmembrane glycoprotein (GP116) interacts with extracellular matrix and ankyrin. Mol Cell Biol. 1992;12(6):4464–4471
  4. Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res. 2007;5(3):553–567
  5. Bourguignon LY. Interactions between the membrane cytoskeleton and CD44 during lymphocyte signal transduction and cell adhesion. Curr Top Membr. 1996;43(2):293–312
  6. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61(5):1303–1313
  7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(3):3983–3998
  8. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104(3):10158–10163
  9. Wright MH, Calcagno AM, Salcidol CD, Carlsonl MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10(1):1–16
  10. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98(2):756–765
  11. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13(2):153–166
  12. Li CW, Heidt DG, Dalerba P, Burant CF, Zhang LJ, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030–1037
  13. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–10951
  14. Takaishi S, Okumura T, Tu SP, Wang SW, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27(2):1006–1020
  15. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol. 2008;26(5):2871–2875
  16. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ. Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. In Vivo. 2007;22(5):89–92
  17. Guzman ML, Jordan CT. Cancer stem cells. N Engl J Med. 2006;21(4):1253–1261
  18. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95(3):930–940
  19. Cheng C, Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol. 2006;(26):362–370
  20. Reategui ER, de Mayolo AA, Das PM, Astor FC, Singal R, Hamilton KL, et al. Characterization of CD44v3-containing isoforms in head and neck cancer. Cancer Biol Ther. 2006;5(1):1163–1168
  21. Liu YJ, Yan PS, Li J, Jia J-F. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol. 2005;11(3):6601–6606
  22. Franzmann EJ, Reategui EF, Carraway KL, Hamilton KJ, Weed DT, Goodwin WJ. Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(4):735–739
  23. Gunthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol. 1993;184(2):47–63
  24. VanHal NLW, Van Dongen GAMS, Stigter-Vanwaasum M, Snow GB, Brakenhoff RH. Characterization of CD44v6 isoforms in head-and-neck squamous cell carcinoma. Int J Cancer. 1999;82(6):837–845
  25. Patrawala L, Calhoun T, Schneider-Broussard R. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25(4):1696–1708
  26. Li C, Heidt DG, Dalerba P. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030–1037
  27. Liu S, Dontu G, Mantle ID. Hedgehog signaling and Bmi-1regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66(5):6063–6071
  28. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355(5):1253–1261
  29. Huang ZH, Li LH, Huang D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 2006;243(3):64–70
  30. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006;24(5):3756–3762
  31. Mehra N, Penning M, Maas J, Beerepoot LV, van Daal N, van Gils CH, et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res. 2006;12(3):4859–4866

PII: S1368-8375(10)00058-8

doi: 10.1016/j.oraloncology.2010.02.011

Oral Oncology
Volume 46, Issue 5 , Pages e29-e33 , May 2010

Article Tools

* Image Usage & Resolution